CS270604B1 - Physiologically active preparation that increases celebral return - Google Patents
Physiologically active preparation that increases celebral return Download PDFInfo
- Publication number
- CS270604B1 CS270604B1 CS849027A CS902784A CS270604B1 CS 270604 B1 CS270604 B1 CS 270604B1 CS 849027 A CS849027 A CS 849027A CS 902784 A CS902784 A CS 902784A CS 270604 B1 CS270604 B1 CS 270604B1
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- physiologically active
- celebral
- return
- increases
- weight
- Prior art date
Links
- NWPRCRWQMGIBOT-UHFFFAOYSA-N 7-(2-hydroxyethyl)-1,3-dimethylpurine-2,6-dione Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CCO)C=N2 NWPRCRWQMGIBOT-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000219 Sympatholytic Substances 0.000 claims abstract description 6
- 229960005387 etofylline Drugs 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 230000000948 sympatholitic effect Effects 0.000 claims abstract description 4
- 210000004958 brain cell Anatomy 0.000 claims abstract description 3
- PBUNVLRHZGSROC-VTIMJTGVSA-N dihydro-alpha-ergocryptine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1 PBUNVLRHZGSROC-VTIMJTGVSA-N 0.000 claims abstract description 3
- SEALOBQTUQIVGU-QNIJNHAOSA-N dihydroergocornine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)N4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1 SEALOBQTUQIVGU-QNIJNHAOSA-N 0.000 claims abstract description 3
- 229960004290 dihydroergocornine Drugs 0.000 claims abstract description 3
- 229960002032 dihydroergocryptine Drugs 0.000 claims abstract description 3
- 230000004060 metabolic process Effects 0.000 claims abstract 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 235000011187 glycerol Nutrition 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 230000003727 cerebral blood flow Effects 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 abstract description 4
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 abstract description 2
- 229960004318 dihydroergocristine Drugs 0.000 abstract description 2
- LIMAOLZSWRJOMG-HJPBWRTMSA-N dihydroergocristine Chemical compound C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(N21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C3=CC=CC4=NC=C([C]34)C2)C1)C(C)C)C1=CC=CC=C1 LIMAOLZSWRJOMG-HJPBWRTMSA-N 0.000 abstract description 2
- 229960001476 pentoxifylline Drugs 0.000 abstract description 2
- 230000002460 anti-migrenic effect Effects 0.000 abstract 1
- 230000036770 blood supply Effects 0.000 abstract 1
- 230000002490 cerebral effect Effects 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 description 12
- 208000028867 ischemia Diseases 0.000 description 10
- 206010019233 Headaches Diseases 0.000 description 8
- 230000001154 acute effect Effects 0.000 description 7
- 231100000869 headache Toxicity 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 208000017932 Steel syndrome Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 208000019695 Migraine disease Diseases 0.000 description 4
- 230000003454 betamimetic effect Effects 0.000 description 4
- 206010027599 migraine Diseases 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 206010047139 Vasoconstriction Diseases 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000010412 perfusion Effects 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 230000025033 vasoconstriction Effects 0.000 description 3
- 206010058842 Cerebrovascular insufficiency Diseases 0.000 description 2
- 230000019522 cellular metabolic process Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000000304 vasodilatating effect Effects 0.000 description 2
- 230000024883 vasodilation Effects 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- 230000001457 vasomotor Effects 0.000 description 2
- RXPRRQLKFXBCSJ-GIVPXCGWSA-N vincamine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C[C@](O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-GIVPXCGWSA-N 0.000 description 2
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 description 1
- GEPMAHVDJHFBJI-UHFFFAOYSA-N 7-[2-hydroxy-3-[2-hydroxyethyl(methyl)amino]propyl]-1,3-dimethylpurine-2,6-dione;pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC=CN=C1.CN1C(=O)N(C)C(=O)C2=C1N=CN2CC(O)CN(CCO)C GEPMAHVDJHFBJI-UHFFFAOYSA-N 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- DDNCQMVWWZOMLN-IRLDBZIGSA-N Vinpocetine Chemical compound C1=CC=C2C(CCN3CCC4)=C5[C@@H]3[C@]4(CC)C=C(C(=O)OCC)N5C2=C1 DDNCQMVWWZOMLN-IRLDBZIGSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000808 adrenergic beta-agonist Substances 0.000 description 1
- FQPFAHBPWDRTLU-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=C1NC=N2.O=C1N(C)C(=O)N(C)C2=C1NC=N2 FQPFAHBPWDRTLU-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 230000003788 cerebral perfusion Effects 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- RXPRRQLKFXBCSJ-UHFFFAOYSA-N dl-Vincamin Natural products C1=CC=C2C(CCN3CCC4)=C5C3C4(CC)CC(O)(C(=O)OC)N5C2=C1 RXPRRQLKFXBCSJ-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- XLMJRFCCCWFQRE-SJRQCXNHSA-N ecboline Chemical class C([C@H]1[C@]2(O)O3)CCN1C(=O)CN2C(=O)[C@]3(C(C)C)NC(=O)[C@@H](CN(C)[C@@H]1C2)C=C1C1=C3C2=CNC3=CC=C1 XLMJRFCCCWFQRE-SJRQCXNHSA-N 0.000 description 1
- 229960003133 ergot alkaloid Drugs 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 150000004005 nitrosamines Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000000810 peripheral vasodilating agent Substances 0.000 description 1
- 229960002116 peripheral vasodilator Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- 229960002726 vincamine Drugs 0.000 description 1
- 229960000744 vinpocetine Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Fyziologicky účinný přípravek zvyšující mozkové prokrvení a upravující metabolismus mozkových buněk. Je použitelný jako geriatrikum a antimigrenikum. Skládá . se z účinných látek beta raimetika v množství 1,75 až 7 hmot. % s výhodou etofylinu nebo pentoxifylinu a alfa sympatolytikum v množství 0,01 až 0,2 hmot. S s výhodou dihydroergocristinu nebo dihydroergocryptinu nebo dihydroergocorninu nebo jejich směsi v poměru 1 s 1 : 1.Physiologically effective preparation increasing cerebral blood supply and metabolism control brain cells. It is usable as geriatrics and anti-migraines. Composes. the active ingredients are beta-rimetics in amounts 1.75 to 7 wt. % preferably etophylline or pentoxifylline and alpha sympatholytic in an amount of 0.01 to 0.2 wt. S preferably dihydroergocristine or dihydroergocryptine or dihydroergocornine or mixtures thereof in a ratio of 1 to 1: 1.
Description
Vynález se týká složení nového fyziologicky účinného přípravku zvyšujícího mozkové prokrveni. a upravujícího metabolismus mozkových buněk. Je ve formě roztoku určeného k užívání v podobě kapek. Dávkování zaručuje kapací vložka. Obsahuje betamimetikum, s výhodou etofylin anebo pentoxifylin a alfa-sympatolytikum vedle farmaceutických pomocných látek. !The invention relates to a composition of a novel physiologically active preparation for increasing cerebral blood flow. and regulating brain cell metabolism. It is in the form of a solution to be used in the form of drops. Dosing is guaranteed by a drip insert. It contains a betamimetic, preferably etophylline or pentoxifylline, and an alpha-sympatholytic in addition to pharmaceutical excipients. !
Ve světě je známý velký počet látek'a př’ípi;ávků z nich, které jsou označovány za terapeutika léčící ischemii CNS. Mezi nejdéle používané patří aminophyllin, který ale pro nepravidelné vstřebávání se z oblasti trávicího traktu je málo účinný. Nejvíce je vyznačen účinek bronchodilatační, na úpravu metabolismu buněk CNS nemá vliv. Zanedbatelný není ani možný vznik nitrosaminů v kyselém obsahu žaludku, jak uvádí četná literatura. .A large number of substances and additives are known in the world, which are termed therapeutics for the treatment of CNS ischemia. One of the longest used is aminophyllin, which is not very effective due to irregular absorption from the gastrointestinal tract. The bronchodilator effect is most marked, it has no effect on the regulation of CNS cell metabolism. The possible formation of nitrosamines in the acidic content of the stomach is not negligible either, as the numerous literature reports. .
Nikotinát xantinolu má dobře vyznačeny účinky vasodilatační na periferii, zatímco ' centrální účinek je klinicky málo významný. V akutní ischemické fázi může ještě zhoršit perfuzi ischemizované oblasti mechanismem steel syndromu, rovněž může vyvolat bolesti· hlavy mechanismem vasodilatace. Pro léčení bolesti hlavy se tato látka nehodí. 'Xanthinol nicotinate has well-marked peripheral vasodilatory effects, while the central effect is clinically insignificant. In the acute ischemic phase, it can worsen the perfusion of the ischemized area by the mechanism of steel syndrome, it can also cause headaches by the mechanism of vasodilation. This substance is not suitable for the treatment of headaches. '
Nitroglycerin je výrazné koronární vasodilatans, ale vasodilatace cév CNS je pravděpodobná. Při terapii migrény ve fázi aury se může úspěšně uplatnit. U ischemii CNS je pravděpodobné, že by vyvolal steel syndrom. ·Nitroglycerin is a prominent coronary vasodilator, but vasodilation of CNS vessels is likely. It can be used successfully in the treatment of migraine in the aura phase. CNS ischemia is likely to cause steel syndrome. ·
Cynaririn je.centrální i periferní vasodilatans, pro možnost vzniku steel syndrom není vhodný u akutních ischemii CNS. Zhoršuje hypotenzi u hypotoniků a vyvolává až závratě. Svým silným vasodilatačním účinkem může vyvolat bolesti hlavy, proto se na terapii cefalgií nehodí. .Cynaririne is a central and peripheral vasodilator, due to the possibility of steel syndrome it is not suitable for acute CNS ischemia. It worsens hypotension in hypotonics and causes dizziness. Due to its strong vasodilating effect, it can cause headaches, so it is not suitable for the treatment of cephalgia. .
Vinpocetin je účinné centrální vasodilatans,. vhodné i k terapii některých bolestí hlavy, není vhodný pro léčbu akutní ischemie CNS. 'Vinpocetine is an effective central vasodilator. also suitable for the treatment of some headaches, not suitable for the treatment of acute CNS ischemia. '
Naftidrofuryl je účinné centrální a zvláště periferní vadodilatans, vhodné k terapii chronických ischemii a sklerosy CNS. Nehodí se pro léčbu akutní ischemie, kde dochází ke zhoršení perfuse kyslíku steel syndromem. Vincamin je účinné vasodilatans periferních i centrálních cév. U léčby akutní ischemie CNS je potřebná opatrnost. Polosyntetické námelové alkaloidy ergotoxinové řady, především.dihydroergocristin, dihydroergocornin, dihydroergocryptin, většinou v podobě solí s kyselinou metansulfonovou jsou velmi vhodné pro svůj alfa-sympatolytický účinek, bez místního vasokonstrikčního účinku k terapii bolestí hlavy a chronických ischemii CNS. Pro léčbu akutní ischemie CNS se pro možnost vzniku steel syndromu nehodí.Naphthidrofuryl is an effective central and especially peripheral vadodilator, suitable for the treatment of chronic ischemia and CNS sclerosis. It is not suitable for the treatment of acute ischemia, where oxygen perfusion is worsened by steel syndrome. Vincamine is an effective vasodilator of peripheral and central vessels. Caution should be exercised when treating acute CNS ischemia. Semi-synthetic ergot alkaloids of the ergotoxin series, especially dihydroergocristine, dihydroergocornine, dihydroergocryptine, mostly in the form of salts with methanesulfonic acid, are very suitable for their alpha-sympatholytic effect, without local vasoconstrictive effect for the treatment of headaches and chronic CNS ischemia. It is not suitable for the treatment of acute CNS ischemia due to the possibility of steel syndrome.
Výše uvedené nedostatky a problémy jsou odstraněny tím, že v přípravku podle vynálezu se pracuje s látkami exaktně používanými ve farmacii, a že se vyšlo z jejich precizně definovaných vlastností, což umožňuje s jistotou předpokládat i výsledný efekt přípravku, toto bylo'potvrzeno i značně obsáhlými klinickými zkouškami.The above-mentioned drawbacks and problems are eliminated by the fact that in the preparation according to the invention the substances are used exactly in pharmacy and by precisely defined their properties, which makes it possible to predict with certainty the final effect of the preparation. clinical trials.
Kombinací beta mimetika a alfa sympatolytika se dosahuje signifikantního zlepšení mozkové perfuse, bez rizika Steel syndromu, protože beta mimeticky působící komponenta etofylin vyvolává relativní hyporvontilaci a tospirační alkal.ozu, která je příčinou parciální vasokonstrikce v neischemické oblasti cévního řečiště CNS a v ischemizované oblasti se účinky vasoaktivních látek neprojeví, a proto dochází k zlepšení perfuze. V ischemizované oblasti nedojde k vasokonstrikci, nýbrž k relativnímu překrvení z okolních oblastí, kde došlo k vasokonstrikci. Uvedená kombinace obou látek je vhodná k terapii vasomotorických bolestí hlavy, tak akutních ischemii CNS nebo jejich forem transitorních ischemických atak - migrény acompagne, tak i chronické cerebrovaskulární insuficience.The combination of beta mimetics and alpha sympatholytics significantly improves cerebral perfusion, without the risk of Steel syndrome, because the beta mimetic component etophylline induces relative hyporvontilation and tospiratory alkalinity, which causes partial vasoconstriction in the nonischemic area of the CNS vascular system and in the ischemized area. vasoactive substances do not show up and therefore perfusion is improved. There is no vasoconstriction in the ischemized area, but relative congestion from the surrounding areas where vasoconstriction has occurred. Said combination of both substances is suitable for the treatment of vasomotor headaches, both acute CNS ischemia or their forms of transient ischemic attacks - migraine acompagne, as well as chronic cerebrovascular insufficiency.
CS 270 604 BlCS 270 604 Bl
Přípravek obsahuje kombinaci složky alfa sympatolytika s výhodou metansulfonátu dihydroergbcristinu 0,01 % až 0,2 % hmot, a beta mimetikum, s výhodou etofylinu 1,75 % až 7 % hmot., látek zabezpečujících stabilitu přípravku, a to jak chemickou, mikrobiologickou, tak dobrou biologickou dostupnost.The preparation contains a combination of an alpha sympatholytic component, preferably dihydroergicin methanesulfonate 0.01% to 0.2% by weight, and a beta mimetic, preferably etophylline 1.75% to 7% by weight, substances which ensure the stability of the preparation, both chemical and microbiological, so good bioavailability.
Dále je předmět vynálezu objasněn na 2 ppíkiladech, aniž by se na tyto omezoval.The subject matter of the invention is further elucidated in 2 examples, without being limited thereto.
Příklad 1 ’ 1 Example 1 ' 1
Příklad 1 - Způsob přípravy .Example 1 - Method of preparation.
Do homogenizačního zařízení se našaržuje za obyčejné-teploty líh a propylenglykoi, pos.tupně se přidávají obě účinné látky a směs se dokonale zhomogenizuje. Po rozpuštění obou účinných látek se přidá potřebné množství vody a znovu se homogenizuje. Potom se roztok zfiltruje a rozplní do lékovek.Alcohol and propylene glycol are charged to the homogenizer at room temperature, then both active ingredients are added in succession and the mixture is completely homogenized. After dissolving the two active ingredients, the required amount of water is added and homogenized again. The solution is then filtered and filled into vials.
Příklad 2Example 2
Pentoxyphyllium 3,50 % hmot.Pentoxyphyllium 3.50 wt.
DH-ergotoxinium mesylicum 0,10 % hmot.DH-ergotoxinium mesylicum 0.10 wt.
Glycerinům 5,00 % hmot.To glycerins 5.00% by weight.
Propylenglykolum 20,00 % hmot.Propylene glycol 20.00% by weight
Spiritus (95 % hmot.) 11,00 % hmot.Spiritus (95% by weight) 11.00% by weight
Aqua demineralisata ad 100,00 % hmot. .Aqua demineralized to 100.00% by weight. .
Příklad 2 - Způsob přípravyExample 2 - Method of preparation
Do homogenizačního zařízení se našaržuje za obyčejné teploty líh, propylenglykoi, glycerin a postupně se přidávají obě účinné látky. Po jejich rozpuštění se přidá potřebné množství vody’a směs dokonale zhomogenizuje. Potom se roztok zfiltruje a rozplní do lékovek.Alcohol, propylene glycol and glycerin are charged to the homogenizer at room temperature and both active ingredients are added in succession. After dissolving them, the required amount of water is added and the mixture is completely homogenized. The solution is then filtered and filled into vials.
Farmakologie přípravku podle vynálezuPharmacology of the preparation according to the invention
Byla určována akutní toxicita na myších a krysách, určila se toxicita po 60-ti denním podávání přípravku, a orgány zvířat, na kterých bylo zkoušeno, byly podrobeny makroskopickému a histologickému zkoumání. Všechny prováděné testy potvrdily neškodnost přípravku.Acute toxicity was determined in mice and rats, toxicity was determined after 60 days of administration, and the organs of the animals tested were subjected to macroscopic and histological examination. All tests performed confirmed the safety of the product.
Klinické zkušenosti s přípravkem podle vynálezuClinical experience with the preparation according to the invention
Zkoušeno' bylo u nemocných migrénou, vasomotorickou bolestí hlavy, Hortonovým syndromem, migrény acompagne, cerebrovaskulární insuficiencí a organickým psychosyndromem v involuci. ·It has been tested in patients with migraine, vasomotor headache, Horton's syndrome, migraine acompagne, cerebrovascular insufficiency and organic psychosyndrome in involution. ·
Došlo k regresi subjektních potíží, tak i objektivního nálezu neurologického. Výhodou je minimální výskyt vedlejších nežádoucích účinků i při dlouhodobém podávání. Přípravek podle vynálezu nezvyšuje krevní tlak. Při předepsaném způsobu užívání je i pronikavě snížena iritace v oblasti gastrointestirálního traktu.There was a regression of subjective problems as well as an objective neurological finding. The advantage is the minimal occurrence of side effects even with long-term administration. The preparation according to the invention does not increase blood pressure. With the prescribed method of use, irritation in the area of the gastrointestinal tract is also significantly reduced.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS849027A CS270604B1 (en) | 1984-11-26 | 1984-11-26 | Physiologically active preparation that increases celebral return |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS849027A CS270604B1 (en) | 1984-11-26 | 1984-11-26 | Physiologically active preparation that increases celebral return |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CS902784A1 CS902784A1 (en) | 1989-12-13 |
| CS270604B1 true CS270604B1 (en) | 1990-07-12 |
Family
ID=5441572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS849027A CS270604B1 (en) | 1984-11-26 | 1984-11-26 | Physiologically active preparation that increases celebral return |
Country Status (1)
| Country | Link |
|---|---|
| CS (1) | CS270604B1 (en) |
-
1984
- 1984-11-26 CS CS849027A patent/CS270604B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CS902784A1 (en) | 1989-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7547435B2 (en) | Topical Formulations of JAK Inhibitors | |
| CN103459394B (en) | Tofacitinib in crystalline and non-crystalline forms, and pharmaceutical compositions comprising tofacitinib and a penetration enhancer | |
| Itoh et al. | Effect of allopurinol on ischemia and reperfusion-induced cerebral injury in spontaneously hypertensive rats. | |
| Edmonson et al. | Effect of reserpine on fatty acid mobilization. | |
| RU2703557C1 (en) | Pharmaceutical composition for local administration | |
| US8754070B2 (en) | Testosterone gel and method of use | |
| BR112018010464B1 (en) | TOPICAL OINTMENT FORMULATION AND USE THEREOF TO TREAT INFLAMMATORY CONDITIONS | |
| FI69753C (en) | FRAMEWORK FOR THE FRAMSTATION OF AV IS SALOR BASIS AV ISOSORBIDINE NITRATES | |
| Yang et al. | Novel 2, 6-disubstituted benzofuran-3-one analogues improve cerebral ischemia/reperfusion injury via neuroprotective and antioxidative effects | |
| CS270604B1 (en) | Physiologically active preparation that increases celebral return | |
| EP1137653B1 (en) | Troxerutin with high trihydroxy-ethyl-rutin content and method for preparing same | |
| JPH039089B2 (en) | ||
| US4305942A (en) | Xanthine oxidase inhibitor and therapeutic treatment using same | |
| CZ287939B6 (en) | Fumarate salt of (R)-5-(methylaminosulfonylmethyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole, process of its preparation, use thereof and pharmaceutical preparation in which it is comprised | |
| RU2618462C2 (en) | Method and improved pharmaceutical composition for acceleration of pde-5 inhibitor transdermal delivery | |
| RU2660353C2 (en) | Method and improved pharmaceutical composition for accelerating the transdermal delivery of a pde-5 inhibitor | |
| JPS627167B2 (en) | ||
| CN116063289A (en) | A kind of crystal form, its preparation method and its application | |
| CN119280250A (en) | A glucocorticoid drug preparation and its preparation method and application | |
| CN114685442A (en) | Salts of pyridinylalkenylpiperidine derivatives and use thereof | |
| HK1169034A (en) | Improved testosterone gel for use in the treatment of hypogonadism | |
| HK40004636A (en) | Improved testosterone gel and method of use | |
| HK40004636B (en) | Improved testosterone gel and method of use |